Reviews/Parkinsons Disease Management/Monoamine oxidase B inhibitors provide motor benefit in Parkinson's
PD MOTOR · PD-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
This corpus tests whether MAO-B inhibitors improve the movement symptoms of Parkinson's disease, either added to levodopa or used alone. The strongest evidence is for safinamide added to levodopa in people whose response fluctuates: three separate placebo-controlled trials across European [1], Japanese [2] and Chinese [3] patients all show more good ON-time, less OFF-time and better motor scores. Support for using these drugs alone, and for selegiline and rasagiline specifically, is much weaker and comes from small studies without a placebo comparison [6][8]. Most of the corpus is about safinamide, which also acts on non-MAO-B targets, so its trial results cannot be read purely as a class effect [7][8]. The panel judged the add-on part of the claim well-established while the monotherapy and non-safinamide parts remain thinly supported.
Three independent double-blind placebo-controlled Phase III trials show safinamide add-on to levodopa improves motor symptoms and reduces OFF-time in fluctuating Parkinson's disease: [1] raises ON-time without troublesome dyskinesia and improves UPDRS Part III, [2] increases mean daily ON-time by 1.39 h (p = 0.0002) and 1.66 h (p < 0.0001), and [3] reduces mean daily OFF time by 1.10 h (p < 0.0001). An uncontrolled single-arm study [4] (n = 199) and a real-world post-hoc cohort [9] reinforce the add-on signal. Monotherapy motor benefit comes from one small drug-naïve observational cohort [6] (N = 27; selegiline 11, rasagiline 16) with a mean 46.5% motor improvement, which also supplies the only selegiline data. Rasagiline motor benefit also appears in a retrospective switch pilot [7] and a prospective rasagiline-controlled study [8]. Across every paper the direction is consistent: motor measures favour MAO-B inhibitor treatment. The contested point: The division is between the RCT-grade adjunct limb and the rest of the claim: the broad class wording names selegiline and rasagiline and covers monotherapy, yet those rest on single-arm, retrospective and observational data [6][7][8][9]. Safinamide's dual dopaminergic and non-dopaminergic mechanism [7][8] further blocks reading its trial efficacy as a clean MAO-B class effect.
All 9 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Parkinsons Disease Management, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The corpus is overwhelmingly safinamide; selegiline is supported only by 11 patients inside a single N=27 observational cohort [6], so the named-drug 'selegiline' portion of the class claim is barely evidenced.
Safinamide is not a pure MAO-B inhibitor; [7] and [8] attribute part of its benefit to Na-channel/glutamatergic action, so safinamide RCT efficacy cannot be read cleanly as an MAO-B class effect.
Where it remains uncertain. Selegiline and monotherapy are supported only by one uncontrolled cohort of 27 drug-naïve patients [6], and safinamide's non-MAO-B actions [7][8] complicate a pure class reading.
Aleatory
The monotherapy and non-safinamide signals come from tiny cohorts (N=27 [6], 17 [7], 45 [8]), where chance variation in a few patients can move the reported effect substantially.
Epistemic
Selegiline appears only as 11 patients within one observational cohort [6]; too little data exists to characterise its motor effect for the named-drug part of the claim.
The load-bearing papers from a corpus of 9, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Phase III RCT: safinamide adjunct motor benefit vs placebo.
“Improvements in off time, UPDRS Part III, and CGI-C were significantly greater in both safinamide groups versus placebo.”
Panel auditInternal validity: high · scope of inference: Safinamide as adjunct to levodopa in PD patients with motor fluctuations over 24 weeks; speaks to the adjunct arm of the claim for safinamide only.Key limitations: motor outcome was a secondary endpoint · fluctuating patients only · safinamide only, not rasagiline or selegiline
Independent Phase II/III RCT confirming adjunct motor benefit.
“As an adjunct to l-DOPA, safinamide safely increased ON-time and improved PD symptoms/signs in PD patients with wearing-off.”
Panel auditInternal validity: high · scope of inference: Safinamide as adjunct to l-DOPA in Japanese PD patients with wearing-off over 24 weeks; adjunct arm of the claim for safinamide only.Key limitations: motor score was not the primary endpoint (ON-time was) · wearing-off patients only · safinamide only
Third independent Phase III RCT in a distinct population.
“Safinamide, as add-on therapy to levodopa, significantly reduced motor fluctuations and improved motor symptoms and quality of life of Chinese patients with idiopathic Parkinson's disease.”
Panel auditInternal validity: high · scope of inference: Safinamide as add-on to levodopa in Chinese PD patients with motor fluctuations over 16 weeks; adjunct arm of the claim for safinamide only.Key limitations: primary endpoint was OFF time not a motor scale · fluctuating patients only · safinamide only
The abstract reports relative benefit of safinamide over rasagiline, which does not establish MAO-B motor benefit versus no MAO-B treatment.
Panel auditInternal validity: low · scope of inference: Relative effect of switching from rasagiline to high-dose safinamide in fluctuating PD patients; within-class comparison only.Key limitations: no placebo or untreated comparison · very small retrospective sample · subjective wearing-off outcome, not a motor rating scale
4 of 9 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Strong, replicated RCT evidence for the adjunct claim but thin, uncontrolled evidence for the monotherapy and non-safinamide portions of this broad class claim warrants Likely rather than Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No controlled selegiline motor trial. The named class includes selegiline, yet it appears only as 11 patients within one observational cohort [6], leaving its motor benefit essentially untested in this corpus. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised placebo-controlled trial of selegiline on motor outcomes (UPDRS/MDS-UPDRS-III) in Parkinson's disease.
Open question: Does selegiline provide a motor benefit comparable to the safinamide evidence in this corpus? Why it is still open: Selegiline is represented only by 11 patients inside one observational cohort [6], with no controlled data.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19